{"component": "definition", "props": {"groups": [{"samples": [{"hash": "kdfUt8L3aWT", "uri": "/contracts/kdfUt8L3aWT#ae", "label": "Cooperative Research and Development Agreement", "score": 31.6812076569, "published": true}, {"hash": "8YP4jSO9hYH", "uri": "/contracts/8YP4jSO9hYH#ae", "label": "Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)", "score": 27.0068454742, "published": true}, {"hash": "7pCjhmYaI6z", "uri": "/contracts/7pCjhmYaI6z#ae", "label": "Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)", "score": 27.0068454742, "published": true}], "snippet": "means any untoward medical occurrence in a Human Subject administered Test Article. An AE does not necessarily have a causal relationship with the Test Article, that is, it can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the Test Article, whether or not it is related to it. See FDA Good Clinical Practice Guideline (International Conference on Harmonisation (ICH) E6: \u201cGood Clinical Practice: Consolidated Guidance, 62 Federal Register 25, 691 (1997)).", "size": 25, "snippet_links": [{"key": "human-subject", "type": "definition", "offset": [43, 56]}, {"key": "test-article", "type": "definition", "offset": [70, 82]}, {"key": "causal-relationship", "type": "definition", "offset": [118, 137]}, {"key": "associated-with", "type": "definition", "offset": [291, 306]}, {"key": "use-of-the-test", "type": "clause", "offset": [311, 326]}, {"key": "related-to", "type": "definition", "offset": [357, 367]}, {"key": "clinical-practice-guideline", "type": "definition", "offset": [385, 412]}, {"key": "federal-register", "type": "definition", "offset": [517, 533]}], "hash": "b1c3aea0e6869a39bff42df50a9e6e8f", "id": 1}, {"samples": [{"hash": "7w8hA2oHi8M", "uri": "/contracts/7w8hA2oHi8M#ae", "label": "Cooperative Research and Development Agreement", "score": 35.364238739, "published": true}, {"hash": "aIW4FQDpYJO", "uri": "/contracts/aIW4FQDpYJO#ae", "label": "Cooperative Research and Development Agreement", "score": 35.3629684448, "published": true}, {"hash": "a1ij35ps5Pc", "uri": "/contracts/a1ij35ps5Pc#ae", "label": "Cooperative Research and Development Agreement", "score": 29.1929416656, "published": true}], "snippet": "means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, as defined under 21 C.F.R \u00a7 312.32. See also FDA Good Clinical Practice Guideline (International Conference on Harmonisation (ICH) E6: \u201cGood Clinical Practice: Consolidated Guidance, 62 Federal Register 25, 691 (1997)).", "size": 12, "snippet_links": [{"key": "associated-with", "type": "definition", "offset": [38, 53]}, {"key": "clinical-practice-guideline", "type": "definition", "offset": [177, 204]}, {"key": "federal-register", "type": "definition", "offset": [309, 325]}], "hash": "550a8226fb87686e414d4f22a6c4de0e", "id": 2}, {"samples": [{"hash": "3AZgovIFOzG", "uri": "/contracts/3AZgovIFOzG#ae", "label": "Asset Transfer and License Agreement (Day One Biopharmaceuticals Holding Co LLC)", "score": 32.3374404907, "published": true}, {"hash": "a0SJ2FRRvQf", "uri": "/contracts/a0SJ2FRRvQf#ae", "label": "Exclusive License and Co Funding Agreement (Arrowhead Pharmaceuticals, Inc.)", "score": 32.0937728882, "published": true}, {"hash": "bN0uNdaaAoT", "uri": "/contracts/bN0uNdaaAoT#ae", "label": "License Agreement (Myovant Sciences Ltd.)", "score": 31.376455307, "published": true}], "snippet": "has the meaning set forth in 21 C.F.R. \u00a7 312.32 and generally means any untoward medical occurrence associated with the use of a product in human subjects, whether or not considered related to such product. An AE does not necessarily have a causal relationship with a product, that is, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of such product.", "size": 12, "snippet_links": [{"key": "associated-with", "type": "definition", "offset": [100, 115]}, {"key": "in-human-subjects", "type": "clause", "offset": [137, 154]}, {"key": "related-to", "type": "definition", "offset": [182, 192]}, {"key": "causal-relationship", "type": "definition", "offset": [241, 260]}], "hash": "10a51d5b98bb0e520740304fd46fe44f", "id": 3}, {"samples": [{"hash": "kAJB5j8tYaQ", "uri": "/contracts/kAJB5j8tYaQ#ae", "label": "Development and Commercialization Agreement (Biomarin Pharmaceutical Inc)", "score": 21.0, "published": true}, {"hash": "eUCLFhab8eH", "uri": "/contracts/eUCLFhab8eH#ae", "label": "Development and Commercialization Agreement (La Jolla Pharmaceutical Co)", "score": 21.0, "published": true}], "snippet": "means any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with administration of a Product. AEs include, without limitation, any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "size": 11, "snippet_links": [{"key": "clinical-investigation-subject", "type": "definition", "offset": [54, 84]}, {"key": "pharmaceutical-product", "type": "definition", "offset": [100, 122]}, {"key": "causal-relationship", "type": "definition", "offset": [161, 180]}, {"key": "administration-of", "type": "clause", "offset": [186, 203]}, {"key": "without-limitation", "type": "clause", "offset": [228, 246]}, {"key": "associated-with", "type": "definition", "offset": [359, 374]}, {"key": "related-to", "type": "definition", "offset": [440, 450]}], "hash": "c11ca47a6debce5bc7b7d7af2c92634a", "id": 4}, {"samples": [{"hash": "hL5o1LpwmnJ", "uri": "/contracts/hL5o1LpwmnJ#ae", "label": "Development and License Agreement (Pharmaceutical Product Development Inc)", "score": 21.6406574249, "published": true}, {"hash": "arB4YAYArL0", "uri": "/contracts/arB4YAYArL0#ae", "label": "Development and License Agreement (Pharmaceutical Product Development Inc)", "score": 21.6406574249, "published": true}, {"hash": "hCYxmW8B3rj", "uri": "/contracts/hCYxmW8B3rj#ae", "label": "Mudelta Development and License Agreement (Furiex Pharmaceuticals, Inc.)", "score": 21.3641338348, "published": true}], "snippet": "shall have the same meaning as in the ICH guidelines (E2A, E2C and E2D) relating to the collection, maintenance analysis and reporting of an adverse event or experience.", "size": 9, "snippet_links": [{"key": "same-meaning", "type": "clause", "offset": [15, 27]}, {"key": "ich-guidelines", "type": "definition", "offset": [38, 52]}, {"key": "relating-to", "type": "definition", "offset": [72, 83]}, {"key": "reporting-of", "type": "clause", "offset": [125, 137]}, {"key": "adverse-event", "type": "clause", "offset": [141, 154]}], "hash": "f48fba750f617b10ee8a8813203d9d1d", "id": 5}, {"samples": [{"hash": "6fBKRnl4i6W", "uri": "/contracts/6fBKRnl4i6W#ae", "label": "Cooperative Research and Development Agreement (Ziopharm Oncology Inc)", "score": 30.7330589294, "published": true}, {"hash": "lvVo9SWEGkj", "uri": "/contracts/lvVo9SWEGkj#ae", "label": "Cooperative Research and Development Agreement (Edge Therapeutics, Inc.)", "score": 30.0650234222, "published": true}, {"hash": "l3h9e14RGGD", "uri": "/contracts/l3h9e14RGGD#ae", "label": "Cooperative Research and Development Agreement", "score": 29.8362159729, "published": true}], "snippet": "means any untoward medical occurrence associated with the use of a Test Article in humans, whether or not considered related to the Test Article (21 C.F.R \u00a7\u00a7 312.32, 308.3; see also FDA Good Clinical Practice Guideline, International Conference on Harmonisation (ICH) E6: \u201cGood Clinical Practice: Consolidated Guidance, 62 Federal Register 25,691 (1997)).", "size": 9, "snippet_links": [{"key": "associated-with", "type": "definition", "offset": [38, 53]}, {"key": "test-article", "type": "definition", "offset": [67, 79]}, {"key": "related-to", "type": "definition", "offset": [117, 127]}, {"key": "clinical-practice-guideline", "type": "definition", "offset": [191, 218]}, {"key": "federal-register", "type": "definition", "offset": [323, 339]}], "hash": "b1c4be6e0a3840e72f0efe1d0ec27143", "id": 6}, {"samples": [{"hash": "bCHJALEwVZM", "uri": "/contracts/bCHJALEwVZM#ae", "label": "License Agreement (Biodelivery Sciences International Inc)", "score": 29.2409305573, "published": true}, {"hash": "ghiUUAwHLoZ", "uri": "/contracts/ghiUUAwHLoZ#ae", "label": "License Agreement (Biodelivery Sciences International Inc)", "score": 28.8548946381, "published": true}, {"hash": "dm2WxSum42o", "uri": "/contracts/dm2WxSum42o#ae", "label": "License and Development Agreement (Biodelivery Sciences International Inc)", "score": 21.0, "published": true}], "snippet": "means any untoward medical occurrence in a patient or clinical investigation subject administered Licensed Products or Demonstration Samples and which does not necessarily have to have a causal relationship with such treatment.", "size": 9, "snippet_links": [{"key": "clinical-investigation-subject", "type": "definition", "offset": [54, 84]}, {"key": "licensed-products", "type": "clause", "offset": [98, 115]}, {"key": "demonstration-samples", "type": "definition", "offset": [119, 140]}, {"key": "causal-relationship", "type": "definition", "offset": [187, 206]}], "hash": "56d7f9101399c5cb2702fa7a813ca6e4", "id": 7}, {"samples": [{"hash": "5lqL0abUwez", "uri": "https://19january2021snapshot.epa.gov/sites/static/files/2018-12/documents/section_c_table_2_text_oar.pdf", "label": "19january2021snapshot.epa.gov", "score": 9.7145786285, "published": false}, {"hash": "g0FsosAqhkk", "uri": "https://www.epa.gov/sites/default/files/2018-12/documents/section_c_table_2_text_oar.pdf", "label": "www.epa.gov", "score": 9.3203287125, "published": false}, {"hash": "eV65NHMlUN7", "uri": "https://www.oregon.gov/deq/rulemaking/Documents/aqp2022m4rules.pdf", "label": "www.oregon.gov", "score": 9.0999317169, "published": false}], "snippet": "means Actual Emissions.", "size": 8, "snippet_links": [{"key": "actual-emissions", "type": "definition", "offset": [6, 22]}], "hash": "6f65b24352c29342a2318d688f92b9ea", "id": 8}, {"samples": [{"hash": "gxK9NOVL6Cd", "uri": "https://www.greenclimate.fund/sites/default/files/document/guidance-risk-management-framework-legal-risk.pdf", "label": "www.greenclimate.fund", "score": 10.7070503235, "published": false}, {"hash": "77CHMJwnDeF", "uri": "https://www.greenclimate.fund/sites/default/files/document/gcf-b28-inf03.pdf", "label": "www.greenclimate.fund", "score": 10.5674200058, "published": false}, {"hash": "bmRmezwsLcH", "uri": "https://www.greenclimate.fund/sites/default/files/document/gcf-b22-24.pdf", "label": "www.greenclimate.fund", "score": 9.6433944702, "published": false}], "snippet": "means accredited entity;", "size": 8, "snippet_links": [{"key": "accredited-entity", "type": "definition", "offset": [6, 23]}], "hash": "87d8d0bd24a2712a4a76787302bb1b29", "id": 9}, {"samples": [{"hash": "kZ8cBkICLxD", "uri": "/contracts/kZ8cBkICLxD#ae", "label": "Option and License Agreement (Sutro Biopharma, Inc.)", "score": 33.1587944031, "published": true}, {"hash": "957F4wASNpd", "uri": "/contracts/957F4wASNpd#ae", "label": "License and Collaboration Agreement (Lyra Therapeutics, Inc.)", "score": 32.603012085, "published": true}, {"hash": "lTdtVvpKZlf", "uri": "/contracts/lTdtVvpKZlf#ae", "label": "Exclusive License Agreement (LianBio)", "score": 32.4880218506, "published": true}], "snippet": "has the meaning set forth in the PRC Measures for the Administration of Reporting and Surveillance of Drug Adverse Events (effective as of July 1, 2011) or the equivalent applicable Laws in any relevant Region, and generally means any untoward medical occurrence associated with the use of a product in human subjects, whether or not considered related to such product. An AE does not necessarily have a causal relationship with a product, that is, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of such product.", "size": 5, "snippet_links": [{"key": "the-prc", "type": "definition", "offset": [29, 36]}, {"key": "administration-of", "type": "clause", "offset": [54, 71]}, {"key": "adverse-events", "type": "clause", "offset": [107, 121]}, {"key": "applicable-laws", "type": "definition", "offset": [171, 186]}, {"key": "relevant-region", "type": "definition", "offset": [194, 209]}, {"key": "associated-with", "type": "definition", "offset": [263, 278]}, {"key": "in-human-subjects", "type": "clause", "offset": [300, 317]}, {"key": "related-to", "type": "definition", "offset": [345, 355]}, {"key": "causal-relationship", "type": "definition", "offset": [404, 423]}], "hash": "fffdd1c12ab9bdc689935b2e8f738428", "id": 10}], "next_curs": "Ck8SSWoVc35sYXdpbnNpZGVyY29udHJhY3RzcisLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiILYWUjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means any untoward medical occurrence in a Human Subject administered Test Article. An AE does not necessarily have a causal relationship with the Test Article, that is, it can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the Test Article, whether or not it is related to it. See FDA Good Clinical Practice Guideline (International Conference on Harmonisation (ICH) E6: \u201cGood Clinical Practice: Consolidated Guidance, 62 Federal Register 25, 691 (1997)).", "size": 281, "title": "AE", "id": "ae", "examples": ["The Contractor\u2019s compliance with these requirements pertains to the applicable type of certified <strong>AE</strong> and the applicable time period (e.g., the Contract Period).", "The Contractor must submit on an annual basis the APM base Contract with highlighted modifications for the next <strong>AE</strong> program year for EOHHS review and approval.", "The subcontract with the <strong>AE</strong> will include a defined and uniform set of performance (per 42 CFR 438.6(c) measures to be incorporated as a factor in the results of any shared savings calculations.", "Prior to transmitting data to <strong>AEs</strong>, the Contractor must complete the necessary quality checks and review data privacy of members to ensure integrity of data transmitted to the <strong>AE</strong> for a member\u2019s attributed months, including checks for completeness of data outlined in ATTACHMENT U.", "MCOs must use the monthly <strong>AE</strong> attribution roster to determine the population eligible for the claims extract.", "The <strong>AE</strong> must certify that they are requesting this data as a HIPAA covered entity or as a business associate of a HIPAA-covered entity and that the requested data reflects the minimum data necessary for the <strong>AE</strong> to effectively conduct its health care operations as an <strong>AE</strong>.", "The <strong>AE</strong> must ensure privacy and security of the data and agree to adhere to any and all applicable State and Federal statutes and regulations relating to confidential health care, behavioral health and substance misuse treatment including but not limited to the Federal Regulation 42 CFR, Part 2; Rhode Island Mental Health Law, R.I. Gen.", "This includes activities to: \u2022 Evaluate the performance of <strong>AE</strong> participants, and <strong>AE</strong> providers/suppliers; \u2022 Trend utilization and total cost of care performance over time to evaluate longitudinal program impacts; \u2022 Conduct quality assessment and improvement activities; and \u2022 Conduct population-based activities to improve the health of its assigned beneficiary population.", "To enable <strong>AEs</strong> to validate that their systems are integrating data accurately, control totals should be supplied to the <strong>AE</strong> with each monthly data set indicating: number of records, total allowed amount for medical and pharmacy claims data set, and number of records and total member months for the eligibility data set.", "Claims for a given performance year should be provided to the <strong>AE</strong> for attributed members until the contractual paid lag is complete."], "related": [["aes", "AES", "<strong>AES</strong>"], ["pace", "PACE", "PACE"], ["ams", "AMS", "AMS"], ["bg", "BG", "BG"], ["ls", "LS", "LS"]], "related_snippets": [], "updated": "2025-08-13T04:24:39+00:00"}, "json": true, "cursor": ""}}